Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma

Bibliographic Details
Main Authors: Yamazaki, N., Uhara, H., Fukushima, S., Uchi, H., Shibagaki, N., Kiyohara, Y., Tsutsumida, A., Namikawa, K., Okuyama, R., Otsuka, Y., Tokudome, T.
Format: Online
Language:English
Published: Springer Berlin Heidelberg 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612320/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612320/

Similar Items